Global Clinical Biomarker Testing Services Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

What is the Clinical Biomarker Testing Services Market Size and Growth Rate?

• As per Data Bridge Market Research analysis, the clinical biomarker testing services market was valued at USD 9.68 billion in 2025 and is projected to reach USD 18.45 billion by 2033, growing at a CAGR of 8.40% from 2026 to 2033.
• The market is experiencing steady growth driven by the increasing demand for personalized medicine, the rising prevalence of chronic diseases, and the growing use of biomarkers in drug development and clinical trials. Biomarker testing services are increasingly utilized to assess drug efficacy, safety, and patient stratification, supporting precision medicine approaches across therapeutic areas.
• The expanding adoption of companion diagnostics, advances in molecular biomarker technologies, and the growing number of clinical research and precision oncology programs are accelerating demand for specialized testing services. Pharmaceutical and biotechnology companies, contract research organizations, and research institutes are increasingly outsourcing biomarker assay development and validation to improve clinical trial efficiency and support targeted therapeutic development.

Market Size & Forecast

• Global Market Value (2025): USD 9.68 Billion
• Expected Market Value (2033): USD 18.45 Billion
• Forecast CAGR (2026–2033): 8.40%
• Leading Region in 2025: North America
• Fastest Growing Region: Asia Pacific

What are the Major Takeaways of the Clinical Biomarker Testing Services Market?

• North America dominated the clinical biomarker testing services market with the largest revenue share of 41.6% in 2025, supported by a well-established biopharmaceutical industry, increasing investments in precision medicine, and extensive clinical research activities.
• Asia-Pacific is expected to be the fastest-growing region at a CAGR of 10.0% from 2026 to 2033, fueled by expanding clinical trial activity, rising healthcare expenditure, growing pharmaceutical outsourcing, and increasing adoption of precision medicine across China, India, and other emerging economies.
• The clinical phases segment led the market with a 58.0% share in 2025, driven by he extensive use of biomarker testing during Phase I, II, and III clinical trials for patient stratification, efficacy assessment, and safety monitoring
• Post-marketing phase are the fastest-growing clinical phase type, projected to register a CAGR of 9.8%, reflecting the surge in emphasis on real-world evidence generation and long-term safety monitoring of approved therapies.
• The biomarker assay development & validation segment dominated the service type category with a 39.5% revenue share in 2025, led by its critical role in developing reliable and reproducible assays for clinical trials and companion diagnostics.
• Molecular biomarkers accounted for 69.0% of the market share in 2025, preferred by widespread adoption of genomic, transcriptomic, and proteomic biomarkers in precision medicine and oncology research.
• The drug discovery & development segment is the fastest-growing application category, with a CAGR of 10.1%, driven by increasing integration of biomarkers throughout the drug development process.

Report Scope and Clinical Biomarker Testing Services Market Segmentation         

What is the Key Trend in the Clinical Biomarker Testing Services Market?

• The integration of multi-omics biomarker testing services is increasingly enabling pharmaceutical and biotechnology companies to improve patient stratification, accelerate precision medicine development, and enhance clinical trial success rates across oncology and other complex therapeutic areas.
• For instance, in June 2025, QIAGEN and Incyte announced a global collaboration to develop a next-generation sequencing (NGS)-based companion diagnostic panel for patients with mutant CALR-expressing myeloproliferative neoplasms, strengthening biomarker-guided precision medicine.
• Multi-omics approaches combining genomics, transcriptomics, proteomics, and metabolomics enable more comprehensive biomarker discovery and improve the identification of predictive and prognostic biomarkers for targeted therapies.
• Contract research organizations and specialized testing laboratories are increasingly investing in next-generation sequencing, digital pathology, and AI-powered biomarker analysis platforms to support precision clinical research programs.
• For instance, in September 2024, QIAGEN launched the QIAcuityDx Digital PCR System for clinical testing in oncology, expanding its digital PCR portfolio into clinical diagnostics and enabling highly precise DNA/RNA quantification to support biomarker testing, liquid biopsy, and precision medicine applications.
• As precision medicine programs and biomarker-driven clinical trials continue to expand worldwide, demand for advanced clinical biomarker testing services is expected to accelerate, reinforcing their role in modern drug development and personalized healthcare.

What are the Key Drivers of the Clinical Biomarker Testing Services Market?

• The rapid expansion of precision medicine and targeted therapeutics has significantly increased demand for clinical biomarker testing services capable of identifying predictive biomarkers, selecting appropriate patients, and supporting regulatory-approved companion diagnostics.
• For instance, in August 2024, the U.S. FDA approved Illumina's TruSight Oncology Comprehensive test, the first FDA-approved comprehensive genomic profiling in vitro diagnostic with companion diagnostic claims, expanding access to biomarker-guided targeted cancer therapies.
• Pharmaceutical companies, biotechnology firms, and contract research organizations are increasingly outsourcing biomarker assay development and validation to improve trial efficiency, accelerate regulatory submissions, and reduce overall development timelines.
• For instance, in October 2024, Labcorp announced the availability of Roche's VENTANA CLDN18 (43-14A) RxDx Assay, the first FDA-approved companion diagnostic to identify gastric and gastroesophageal junction cancer patients eligible for VYLOY (zolbetuximab-clzb), expanding access to biomarker-guided precision oncology testing
• With drug developers increasingly relying on biomarker-guided clinical trials to improve treatment outcomes and regulatory success, clinical biomarker testing services will remain essential for advancing precision medicine and next-generation therapeutics.

Which Factors are Challenging the Growth of the Clinical Biomarker Testing Services Market?

• Advanced clinical biomarker testing services require substantial investment in next-generation sequencing platforms, specialized laboratory infrastructure, bioinformatics capabilities, and highly trained scientific personnel to ensure reliable clinical results.
• These high operational and validation costs limit adoption among smaller laboratories, regional healthcare providers, and research organizations with constrained financial and technical resources.
• For instance, in September 2024, the International Association for the Study of Lung Cancer (IASLC) reported that limited reimbursement, high testing costs, and long turnaround times remain major barriers to comprehensive biomarker testing adoption across healthcare systems worldwide
• The increasing complexity of regulatory compliance, quality assurance requirements, and reimbursement uncertainties continues to raise service costs and delay implementation across emerging healthcare markets and smaller diagnostic laboratories.
• For instance, in May 2024, an article published in JAMA highlighted that inconsistent insurance coverage and varying state biomarker testing policies continue to limit equitable patient access to clinically recommended biomarker testing in the United States.
• These financial and regulatory barriers continue to restrict broader adoption of advanced clinical biomarker testing services, particularly in cost-sensitive regions, despite increasing demand for precision medicine and biomarker-driven clinical research.

How is the Clinical Biomarker Testing Services Market Segmented?

The clinical biomarker testing services market is segmented on the basis of clinical phase, service, biomarker type, application, and end user.

• By Clinical Phase

On the basis of clinical phase, the clinical biomarker testing services market is segmented into preclinical phase, clinical phases, and post-marketing phase. The clinical phases segment dominated the market with an estimated share of 58.0% in 2025, driven by the extensive use of biomarker testing during Phase I, II, and III clinical trials for patient stratification, efficacy assessment, and safety monitoring. Pharmaceutical and biotechnology companies increasingly rely on biomarker testing services to improve trial success rates and accelerate regulatory approvals. Growing adoption of precision medicine and companion diagnostics has significantly increased demand for biomarker-based clinical trial services. Advanced molecular profiling technologies are enabling more accurate patient selection and treatment response evaluation. Increasing outsourcing of biomarker analysis to specialized service providers is further supporting segment growth.

The post-marketing phase segment is projected to register the fastest growth at an estimated CAGR of 9.8% from 2026 to 2033, driven by increasing emphasis on real-world evidence generation and long-term safety monitoring of approved therapies. Biomarker testing is increasingly being used to evaluate treatment effectiveness and identify patient populations that benefit most from targeted therapies. Growing regulatory focus on post-market surveillance is encouraging pharmaceutical companies to expand biomarker monitoring programs. Advances in real-world data analytics and digital health platforms are improving long-term biomarker assessment. Rising adoption of personalized medicine is also supporting continued patient monitoring after commercialization. Increasing demand for outcome-based healthcare is expected to accelerate growth in this segment.

• By Service

On the basis of service, the clinical biomarker testing services market is segmented into biomarker assay development & validation, biomarker identification, biomarker profiling, and others. The biomarker assay development & validation segment dominated the market with an estimated share of 39.5% in 2025, owing to its critical role in developing reliable and reproducible assays for clinical trials and companion diagnostics. Pharmaceutical companies require validated biomarker assays to ensure analytical accuracy and regulatory compliance throughout drug development. The growing number of targeted therapies and precision medicine programs continues to increase demand for assay validation services. Service providers are investing in advanced analytical technologies to improve assay sensitivity and specificity. Increasing regulatory expectations for biomarker qualification further support demand.

The biomarker profiling segment is projected to witness the fastest growth at an estimated CAGR of 10.4% from 2026 to 2033, driven by increasing adoption of comprehensive molecular profiling using genomics, transcriptomics, proteomics, and metabolomics. Biomarker profiling enables deeper understanding of disease biology and supports precision therapeutic development. The growing use of next-generation sequencing and multi-omics technologies is significantly expanding profiling capabilities. Pharmaceutical companies are increasingly utilizing biomarker profiling to identify predictive and prognostic biomarkers. Rising demand for personalized treatment strategies is accelerating investment in advanced profiling services. Continuous innovation in bioinformatics and artificial intelligence is further supporting rapid market growth.

• By Biomarker Type

On the basis of biomarker type, the clinical biomarker testing services market is segmented into molecular biomarkers and cellular biomarkers. The molecular biomarkers segment dominated the market with an estimated share of 69.0% in 2025, driven by widespread adoption of genomic, transcriptomic, and proteomic biomarkers in precision medicine and oncology research. These biomarkers are extensively used for disease diagnosis, patient stratification, and treatment selection. Increasing use of next-generation sequencing and polymerase chain reaction technologies continues to expand molecular biomarker applications. Pharmaceutical companies increasingly rely on molecular biomarkers to support companion diagnostic development. Continuous advances in genomic medicine are improving biomarker discovery and clinical utility.

The cellular biomarkers segment is expected to register the fastest growth at an estimated CAGR of 9.6% from 2026 to 2033, supported by increasing adoption of cell-based immunotherapies and personalized medicine approaches. Cellular biomarkers are gaining importance in monitoring immune responses and evaluating treatment efficacy in cancer and autoimmune diseases. Growing investments in flow cytometry and single-cell analysis technologies are expanding research capabilities. The rapid development of CAR-T cell therapies is further increasing demand for cellular biomarker testing. Advancements in high-dimensional immune profiling are improving clinical decision-making. Expanding applications in translational research are expected to sustain strong growth.

• By Application

On the basis of application, the clinical biomarker testing services market is segmented into oncology, drug discovery & development, and others. The oncology segment dominated the market with an estimated share of 54.0% in 2025, owing to the increasing prevalence of cancer and the growing adoption of biomarker-driven precision oncology. Biomarker testing plays a vital role in identifying actionable mutations, selecting targeted therapies, and monitoring treatment response. The expanding number of companion diagnostic approvals continues to increase demand for oncology biomarker services. Pharmaceutical companies are heavily investing in biomarker-based oncology clinical trials to improve therapeutic outcomes. Advances in molecular diagnostics and liquid biopsy technologies are further strengthening market demand.

The drug discovery & development segment is projected to witness the fastest growth at an estimated CAGR of 10.1% from 2026 to 2033, driven by increasing integration of biomarkers throughout the drug development process. Biomarker testing supports target identification, patient enrichment, pharmacodynamic evaluation, and clinical trial optimization. Pharmaceutical companies are increasingly outsourcing biomarker services to improve development efficiency and reduce costs. The expansion of biologics and gene therapies is creating additional opportunities for biomarker-based drug development. Artificial intelligence and multi-omics technologies are enhancing biomarker discovery workflows. Growing investment in precision therapeutics continues to accelerate segment growth.

• By End User

On the basis of end user, the clinical biomarker testing services market is segmented into pharmaceutical & biotechnology companies, research institutes, and contract research organizations (CROs). The pharmaceutical & biotechnology companies segment dominated the market with an estimated share of 52.0% in 2025, driven by increasing investment in biomarker-guided drug discovery, precision medicine, and companion diagnostic development. These organizations extensively utilize biomarker testing services to improve clinical trial efficiency and enhance regulatory success. Rising development of targeted therapies is increasing demand for specialized biomarker assays. Strategic outsourcing of testing services enables companies to reduce operational complexity and accelerate development timelines. Growing R&D expenditure across the biopharmaceutical industry further supports market expansion.

The contract research organizations (CROs) segment is expected to witness the fastest growth at an estimated CAGR of 10.3% from 2026 to 2033, fueled by increasing outsourcing of clinical trials and biomarker testing activities by pharmaceutical and biotechnology companies. CROs provide integrated biomarker services that improve operational efficiency and reduce development costs. Growing complexity of global clinical trials is increasing demand for specialized biomarker expertise. Expansion of precision medicine research is creating new outsourcing opportunities. Continuous investment in advanced laboratory technologies and bioinformatics platforms is strengthening CRO capabilities. Rising demand for end-to-end clinical development services is expected to drive robust growth in this segment.

Which Region Holds the Largest Share of the Clinical Biomarker Testing Services Market?

• North America dominated the clinical biomarker testing services market with the largest revenue share of 41.6% in 2025, supported by a well-established biopharmaceutical industry, increasing investments in precision medicine, and extensive clinical research activities.
• The region also benefits from a high volume of clinical trials, widespread adoption of companion diagnostics, favorable research funding, and growing use of advanced molecular technologies across oncology, drug development, and translational research applications. Increasing demand for personalized medicine and continuous innovation in biomarker discovery and validation continue to strengthen North America's leadership position in the global market.

U.S. Clinical Biomarker Testing Services Market Insight

The U.S. clinical biomarker testing services market is witnessing strong growth due to rising investments in precision medicine, expanding oncology clinical trials, and increasing adoption of companion diagnostics. The country's well-established biopharmaceutical industry, advanced molecular diagnostics infrastructure, and strong presence of leading contract research organizations are driving demand for biomarker testing services across drug development and clinical research. Growing FDA approvals of targeted therapies and companion diagnostics are further accelerating biomarker-guided treatment approaches. In addition, the increasing adoption of next-generation sequencing (NGS), liquid biopsy, and multi-omics technologies is improving biomarker discovery and validation. According to the U.S. Food and Drug Administration (FDA), more than 75 companion diagnostic devices have been approved to support targeted therapies, highlighting the growing integration of biomarker testing into precision healthcare.

Asia-Pacific Clinical Biomarker Testing Services Market Insight

The Asia-Pacific clinical biomarker testing services market is expected to witness rapid growth, driven by increasing clinical trial activity, expanding pharmaceutical outsourcing, and rising investments in precision medicine across China, India, Japan, and South Korea. Growing healthcare expenditure, improving genomic research infrastructure, and increasing adoption of molecular diagnostics are supporting regional market expansion. Governments and private organizations are investing heavily in precision medicine programs and biotechnology innovation, creating strong demand for biomarker testing services. The region is also emerging as a preferred destination for global clinical trials because of its large patient population and improving regulatory environment. According to IQVIA's Global Trends in R&D report, Asia-Pacific continues to account for a rapidly increasing share of global clinical trials, driving demand for outsourced biomarker testing and central laboratory services.

Japan Clinical Biomarker Testing Services Market Insight

The Japan clinical biomarker testing services market is witnessing consistent growth due to increasing investment in genomic medicine, precision oncology, and biomarker-guided therapeutic development. Pharmaceutical companies, academic medical centers, and research institutes are expanding the use of molecular biomarker testing to improve patient stratification and targeted treatment selection. Government initiatives promoting personalized healthcare and advanced genomic sequencing are further strengthening market growth. The growing adoption of companion diagnostics and increasing collaboration between industry and research institutions continue to enhance biomarker-based clinical research. Japan's National Cancer Center has established a nationwide Cancer Genomic Medicine program with designated genomic medicine hospitals to expand access to genomic testing and precision oncology services.

China Clinical Biomarker Testing Services Market Insight

The China clinical biomarker testing services market is growing rapidly, driven by expanding biopharmaceutical research, increasing oncology clinical trials, and strong government support for precision medicine initiatives. Growing adoption of next-generation sequencing, molecular diagnostics, and companion diagnostics across hospitals, biotechnology companies, and research organizations is significantly boosting market demand. Increasing investment in domestic biotechnology innovation and translational research is accelerating biomarker discovery and validation. The country's expanding healthcare infrastructure and favorable government policies are also encouraging international pharmaceutical companies to conduct biomarker-driven clinical studies in China. China's Precision Medicine Initiative, supported by the Ministry of Science and Technology, has invested significantly in genomic research and biomarker discovery to accelerate precision medicine development nationwide.

U.K. Clinical Biomarker Testing Services Market Insight

The U.K. clinical biomarker testing services market is experiencing steady growth, supported by increasing precision medicine research, expanding genomic testing programs, and rising adoption of biomarker-guided clinical trials. Growing collaborations among academic institutions, pharmaceutical companies, and healthcare providers are contributing to market expansion. The National Health Service (NHS) continues to integrate genomic medicine into routine clinical practice, increasing the utilization of molecular biomarker testing. Advances in artificial intelligence, bioinformatics, and large-scale genomic databases are further strengthening biomarker discovery and personalized treatment strategies. Genomics England continues to support nationwide implementation of whole-genome sequencing through the NHS, significantly expanding precision medicine and biomarker research across the country.

Germany Clinical Biomarker Testing Services Market Insight

The Germany clinical biomarker testing services market is expanding steadily due to the country's strong biotechnology sector, advanced molecular diagnostics capabilities, and increasing participation in precision oncology research. Pharmaceutical companies, research institutes, and university hospitals are increasingly utilizing biomarker testing services to support translational research, companion diagnostics, and targeted drug development. Strong public funding for cancer research and personalized medicine initiatives continues to stimulate innovation in biomarker discovery. Increasing adoption of next-generation sequencing and molecular pathology is further strengthening clinical biomarker applications. The German Cancer Consortium (DKTK) continues to expand nationwide translational cancer research programs focused on molecular biomarkers and precision oncology, supporting growing demand for advanced biomarker testing services.

Which are the Top Companies in Clinical Biomarker Testing Services Market?

The clinical biomarker testing services industry is primarily led by well-established companies, including:

• Labcorp (U.S.)
• IQVIA Inc. (U.S.)
• QIAGEN (Netherlands)
• Thermo Fisher Scientific Inc. (U.S.)
• Charles River Laboratories (U.S.)
• ICON plc (Ireland)
• Medpace (U.S.)
• Eurofins Scientific SE (Luxembourg)
• SGS Société Générale de Surveillance SA (Switzerland)
• NAMSA (U.S.)
• BioAgilytix Labs (U.S.)
• Precision Medicine Group, LLC. (U.S.)
• Frontage Labs (U.S.)
• NeoGenomics Laboratories (U.S.)
• GeneDx, LLC (U.S.)
• Guardant Health, Inc. (U.S.)
• Foundation Medicine, Inc. (U.S.)
• Personalis, Inc. (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)

What are Latest Developments in Clinical Biomarker Testing Services Market?

• In July 2025, Illumina launched TruSight Oncology 500 v2, the next generation of its flagship cancer research assay. The assay features built-in homologous recombination deficiency (HRD) biomarker detection, reduced tissue input requirements, and faster turnaround times, supporting comprehensive genomic profiling and biomarker-driven precision oncology research.
• In April 2025, QIAGEN launched new QIAseq Comprehensive Genomic Profiling (CGP) Panels to enhance cancer biomarker analysis in research and clinical applications. The new panels analyze more than 700 genes and support biomarker discovery, precision oncology, and next-generation sequencing workflows, enabling more comprehensive genomic profiling for biomarker-guided drug development
• In September 2024, QIAGEN launched the QIAcuityDx Digital PCR System for clinical oncology testing. The platform enables highly sensitive DNA and RNA quantification for biomarker testing, minimal residual disease monitoring, liquid biopsy applications, and precision medicine, expanding digital PCR capabilities for clinical laboratories.
• In August 2024, Illumina announced FDA approval and commercial launch of TruSight Oncology Comprehensive (TSO Comprehensive), the first FDA-approved comprehensive genomic profiling in vitro diagnostic kit with multiple companion diagnostic claims. The test analyzes more than 500 cancer-related genes in a single assay to support biomarker-guided treatment selection and precision oncology
• In May 2024, QIAGEN launched the QIAseq Multimodal DNA/RNA Library Kit, enabling simultaneous preparation of DNA and RNA libraries from a single sample for next-generation sequencing. The kit supports multiomic studies, comprehensive genomic profiling, biomarker discovery, and precision medicine research by improving workflow efficiency while conserving valuable clinical samples.

SKU-76608